Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Janssen, ViiV to Develop Single Tablet Regimen for HIV | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Janssen, ViiV to Develop Single Tablet Regimen for HIV

Aims to offer a better treatment option for patients

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Janssen R&D Ireland has entered a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen’s Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (EDURANT) and ViiV’s Integrase Inhibitor dolutegravir (TIVICAY), as the sole active ingredients for the maintenance treatment of HIV. The companies will also investigate development of the drug combination for pediatric use.
 
If approved, this treatment could offer an option for patients to switch from a standard three-drug therapy to a two-drug, Nucleoside Reverse Transcriptase Inhibitor (NRTI)-sparing antiviral regimen.  
 
“HIV remains a significant medical challenge, and our goal is to find new treatment regimens for patients,” said Paul Stoffels, chief scientific officer, Johnson & Johnson and Worldwide Chairman, Janssen. “We are pleased to collaborate with ViiV Healthcare in pursuing this shift in the HIV treatment paradigm and reaffirm our commitment to collaborate and develop new HIV treatments and fixed-dose regimens.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics